Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepMIND3: Transdermal Nicotine for Late-Life Depression
NCT05746273Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2023
- Primary completion
- Jul 2026
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotine patch in major depressive disorder (MDD), sponsored by Vanderbilt University Medical Center. Started Apr 2023; status: completed.
02
Drugs
nicotine patch
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05746273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746273.